This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, S. Articles by Wallner, B. P. Search for Related Content PubMed PubMed Citation Articles by Adams, S. Articles by Wallner, B. P.

PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism

¹ Point Therapeutics, Inc., Boston, Massachusetts, and ² Department of Molecular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

The amino boronic dipeptide, PT-100 (Val-boro-Pro), a dipeptidyl peptidase (DPP) inhibitor, has been shown to up-regulate gene expression of certain cytokines in hematopoietic tissue via a high-affinity interaction, which appears to involve fibroblast activation protein. Because fibroblast activation protein is also expressed in stroma of lymphoid tissue and tumors, the effect of PT-100 on tumor growth was studied in mice in vivo. PT-100 has no direct cytotoxic effect on tumors in vitro. Oral administration of PT-100 to mice slowed growth of syngeneic tumors derived from fibrosarcoma, lymphoma, melanoma, and mastocytoma cell lines. In WEHI 164 fibrosarcoma and EL4 and A20/2J lymphoma models, PT-100 caused regression and rejection of tumors. The antitumor effect appeared to involve tumor-specific CTL and protective immunological memory. PT-100 treatment of WEHI 164-inoculated mice increased mRNA expression of cytokines and chemokines known to promote T-cell priming and chemoattraction of T cells and innate effector cells. The role of innate activity was further implicated by observation of significant, although reduced, inhibition of WEHI 164 and A20/2J tumors in immunodeficient mice. PT-100 also demonstrated ability to augment antitumor activity of rituximab and trastuzumab in xenograft models of human CD20⁺ B-cell lymphoma and HER-2⁺ colon carcinoma where antibody-dependent cytotoxicity can be mediated by innate effector cells responsive to the cytokines and chemokines up-regulated by PT-100. Although CD26/DPP-IV is a potential target for PT-100 in the immune system, it appeared not to be involved because antitumor activity and stimulation of cytokine and chemokine production was undiminished in CD26^–/– mice.

This article has been cited by other articles:

				L. R. Henry, H.-O. Lee, J. S. Lee, A. Klein-Szanto, P. Watts, E. A. Ross, W.-T. Chen, and J. D. Cheng Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1736 - 1741. [Abstract] [Full Text] [PDF]

				C. Y. Edosada, C. Quan, C. Wiesmann, T. Tran, D. Sutherlin, M. Reynolds, J. M. Elliott, H. Raab, W. Fairbrother, and B. B. Wolf Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity J. Biol. Chem., March 17, 2006; 281(11): 7437 - 7444. [Abstract] [Full Text] [PDF]

				S. S. Singhal, Y. C. Awasthi, and S. Awasthi Regression of Melanoma in a Murine Model by RLIP76 Depletion Cancer Res., February 15, 2006; 66(4): 2354 - 2360. [Abstract] [Full Text] [PDF]

				J. D. Cheng, M. Valianou, A. A. Canutescu, E. K. Jaffe, H.-O. Lee, H. Wang, J. H. Lai, W. W. Bachovchin, and L. M. Weiner Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth Mol. Cancer Ther., March 1, 2005; 4(3): 351 - 360. [Abstract] [Full Text] [PDF]

				A. Al-Katib, D. D. Hurd, R. Raju, J. Stephenson, F. Giles, E. Haltom, and M. J. Uprichard Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin's Lymphoma with Primary Resistance to or Progression Following Rituximab. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1403 - 1403. [Abstract]